|
Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment. |
|
|
Patents, Royalties, Other Intellectual Property - Bifidobacterium longum subsp. infantis Bg40721_2D9_SN_2018 for the treatment and/or prevention of acute malnutrition in infants and young children. (This is pending).; Cancer detection utilizing normal tissue adjacent to breast tumors with genetic ancestry mapping (filed, not received) (I); Diagnostic Methods for detection of cancer (US patent #9,200,325) - 2015 (I); FOXA1 in prediction of efficacy of hormonal therapy in breast cancer (PCT/US2008/52397-patent pending)- Licensed to Clarient, Inc (I); IU hMuSC cell line (in process) - 2020 (I); Methods for early detection of breast cancer (63/074101) filed - 2020 (I); Patent Awarded – Use of Parthenolide to Inhibit Cancer (6890946) issued on 5/10/2005- co-founded Leuchemix, Inc (currently relinquished the company stakes) (I); Prognostic Indicator for Metastatic Prostate Cancer (patent issued on 4/02/19 US patent 10,247,732 B2) (I) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Cigna |
Research Funding - Astellas Pharma; Decibel Therapeutics (Inst); Seagen |
Other Relationship - UpToDate |
|
|
Honoraria - Abbvie; Astellas Pharma; Bayer; Janssen |
Research Funding - Bayer; Janssen |
Travel, Accommodations, Expenses - Janssen |
|
|
Research Funding - Astellas Pharma (Inst); Merck Sharp & Dohme (Inst) |
|
|
Consulting or Advisory Role - Exelixis; Novartis; Novartis |
Research Funding - Astellas Pharma (Inst) |
|
Christian K. Kollmannsberger |
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Merck KGaA; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Janssen; Merck; Merck KGaA; Pfizer |
Travel, Accommodations, Expenses - Ipsen; Pfizer |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - Patent Awarded for a new drug combination (hormone, anti-inflammatory) to treat age-related hearing loss. (Inst); Patent awarded for new neural stimulation technique involving laser light and gold nanoparticles (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |